|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodrigues Oliveira FF, Dos Santos RE, de
Oliveira AL, de Lima Rozenowicz R, de Melo MB and Scheffer DK:
Prognostic assessment of polymorphisms of the MDR-1 and GSTP1 genes
in patients with stage II and III breast cancer submitted to
neoadjuvant chemotherapy. Breast J. 18:185–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Horak CE, Pusztai L, Xing G, Trifan OC,
Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis
of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone
or paclitaxel in early-stage breast cancer. Clin Cancer Res.
19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Silva JM, Dominguez G, Silva J, Garcia JM,
Sanchez A, Rodriguez O, Provencio M, España P and Bonilla F:
Detection of epithelial messenger RNA in the plasma of breast
cancer patients is associated with poor prognosis tumor
characteristics. Clin Cancer Res. 7:2821–2825. 2001.PubMed/NCBI
|
|
5
|
Cianfrocca M and Gradishar W: New
molecular classifications of breast cancer. CA Cancer J Clin.
59:303–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thanos D and Maniatis T: Virus induction
of human IFN beta gene expression requires the assembly of an
enhanceosome. Cell. 83:1091–1100. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reeves R and Nissen MS: The
A.T-DNA-binding domain of mammalian high mobility group I
chromosomal proteins. A novel peptide motif for recognizing DNA
structure. J Biol Chem. 265:8573–8582. 1990.PubMed/NCBI
|
|
8
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
9
|
Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla
LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau
C, et al: Prediction of central nervous system embryonal tumour
outcome based on gene expression. Nature. 415:436–442. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Narita M, Narita M, Krizhanovsky V, Nuñez
S, Chicas A, Hearn SA, Myers MP and Lowe SW: A novel role for
high-mobility group a proteins in cellular senescence and
heterochromatin formation. Cell. 126:503–514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Adair JE, Maloney SC, Dement GA, Wertzler
KJ, Smerdon MJ and Reeves R: High-mobility group A1 proteins
inhibit expression of nucleotide excision repair factor xeroderma
pigmentosum group A. Cancer Res. 67:6044–6052. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chiappetta G, Botti G, Monaco M,
Pasquinelli R, Pentimalli F, Di Bonito M, D'Aiuto G, Fedele M,
Iuliano R, Palmieri EA, et al: HMGA1 protein overexpression in
human breast carcinomas: Correlation with ErbB2 expression. Clin
Cancer Res. 10:7637–7644. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liau SS, Jazag A and Whang EE: HMGA1 is a
determinant of cellular invasiveness and in vivo metastatic
potential in pancreatic adenocarcinoma. Cancer Res. 66:11613–11622.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piscuoglio S, Zlobec I, Pallante P, Sepe
R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A
and Karamitopoulou E: HMGA1 and HMGA2 protein expression correlates
with advanced tumour grade and lymph node metastasis in pancreatic
adenocarcinoma. Histopathology. 60:397–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fedele M, Fidanza V, Battista S,
Pentimalli F, Klein-Szanto AJ, Visone R, De Martino I, Curcio A,
Morisco C, Del Vecchio L, et al: Haploinsufficiency of the Hmga1
gene causes cardiac hypertrophy and myelo-lymphoproliferative
disorders in mice. Cancer Res. 66:2536–2543. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liau SS, Rocha F, Matros E, Redston M and
Whang E: High mobility group AT-hook 1 (HMGA1) is an independent
prognostic factor and novel therapeutic target in pancreatic
adenocarcinoma. Cancer. 113:302–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liau SS and Whang E: HMGA1 is a molecular
determinant of chemoresistance to gemcitabine in pancreatic
adenocarcinoma. Clin Cancer Res. 14:1470–1477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Williams MD, Zhang X, Belton AS, Xian L,
Huso T, Park JJ, Siems WF, Gang DR, Resar LM, Reeves R and Hill HH
Jr: HMGA1 drives metabolic reprogramming of intestinal epithelium
during hyperproliferation, polyposis, and colorectal
carcinogenesis. J Proteome Res. 14:1420–1431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dolde CE, Mukherjee M, Cho C and Resar LM:
HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat.
71:181–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pegoraro S, Ros G, Ciani Y, Sgarra R,
Piazza S and Manfioletti G: A novel HMGA1-CCNE2-YAP axis regulates
breast cancer aggressiveness. Oncotarget. 6:19087–19101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pegoraro S, Ros G, Piazza S, Sommaggio R,
Ciani Y, Rosato A, Sgarra R, Del Sal G and Manfioletti G: HMGA1
promotes metastatic processes in basal-like breast cancer
regulating EMT and stemness. Oncotarget. 4:1293–1308. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Treff NR, Dement GA, Adair JE, Britt RL,
Nie R, Shima JE, Taylor WE and Reeves R: Human KIT ligand promoter
is positively regulated by HMGA1 in breast and ovarian cancer
cells. Oncogene. 23:8557–8562. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu WM, Guerra-Vladusic FK, Kurakata S,
Lupu R and Kohwi-Shigematsu T: HMG-I(Y) recognizes base-unpairing
regions of matrix attachment sequences and its increased expression
is directly linked to metastatic breast cancer phenotype. Cancer
Res. 59:5695–5703. 1999.PubMed/NCBI
|
|
24
|
Reeves R, Edberg DD and Li Y:
Architectural transcription factor HMGI(Y) promotes tumor
progression and mesenchymal transition of human epithelial cells.
Mol Cell Biol. 21:575–594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Resar LM: The high mobility group A1 gene:
Transforming inflammatory signals into cancer? Cancer Res.
70:436–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baldassarre G, Belletti B, Battista S,
Nicoloso MS, Pentimalli F, Fedele M, Croce CM and Fusco A: HMGA1
protein expression sensitizes cells to cisplatin-induced cell
death. Oncogene. 24:6809–6819. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Cello F, Shin J, Harbom K and Brayton
C: Knockdown of HMGA1 inhibits human breast cancer cell growth and
metastasis in immunodeficient mice. Biochem Biophys Res Commun.
434:70–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manson JE, Colditz GA, Stampfer MJ,
Willett WC, Rosner B, Monson RR, Speizer FE and Hennekens CH: A
prospective study of obesity and risk of coronary heart disease in
women. N Engl J Med. 322:882–889. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song YM, Sung J, Smith Davey G and Ebrahim
S: Body mass index and ischemic and hemorrhagic stroke: A
prospective study in Korean men. Stroke. 35:831–836. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reeves GK, Pirie K, Beral V, Green J,
Spencer E and Bull D: Million Women Study Collaboration: Cancer
incidence and mortality in relation to body mass index in the
Million Women Study: Cohort study. BMJ. 335:11342007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sparano JA, Wang M, Zhao F, Stearns V,
Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr,
et al: Obesity at diagnosis is associated with inferior outcomes in
hormone receptor-positive operable breast cancer. Cancer.
118:5937–5946. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Berclaz G, Li S, Price KN, Coates AS,
Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien
D, Collins J, et al: Body mass index as a prognostic feature in
operable breast cancer: The international breast cancer study group
experience. Ann Oncol. 15:875–884. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chan DS, Vieira AR, Aune D, Bandera EV,
Greenwood DC, McTiernan A, Rosenblatt Navarro D, Thune I, Vieira R
and Norat T: Body mass index and survival in women with breast
cancer-systematic literature review and meta-analysis of 82
follow-up studies. Ann Oncol. 25:1901–1914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Widschwendter P, Friedl TW, Schwentner L,
DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K,
Weissenbacher T, et al: The influence of obesity on survival in
early, high-risk breast cancer: Results from the randomized SUCCESS
A trial. Breast Cancer Res. 17:1292015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Califano D, Pignata S, Losito NS, Ottaiano
A, Greggi S, De Simone V, Cecere S, Aiello C, Esposito F, Fusco A
and Chiappetta G: High HMGA2 expression and high body mass index
negatively affect the prognosis of patients with ovarian cancer. J
Cell Physiol. 229:53–59. 2014.PubMed/NCBI
|
|
37
|
Adult weight determination. The national
health and family planning commission of the People's Republic of
China. 2013 04 18;
|
|
38
|
Huang R, Huang D, Dai W and Yang F:
Overexpression of HMGA1 correlates with the malignant status and
prognosis of breast cancer. Mol Cell Biochem. 404:251–257. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fedele M and Fusco A: HMGA and cancer.
Biochim Biophys Acta. 1799:48–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ram TG, Reeves R and Hosick HL: Elevated
high mobility group-I(Y) gene expression is associated with
progressive transformation of mouse mammary epithelial cells.
Cancer Res. 53:2655–2660. 1993.PubMed/NCBI
|
|
41
|
Flohr AM, Rogalla P, Bonk U, Puettmann B,
Buerger H, Gohla G, Packeisen J, Wosniok W, Loeschke S and
Bullerdiek J: High mobility group protein HMGA1 expression in
breast cancer reveals a positive correlation with tumour grade.
Histol Histopathol. 18:999–1004. 2003.PubMed/NCBI
|
|
42
|
Ganz ML, Wintfeld N, Li Q, Alas V, Langer
J and Hammer M: The association of body mass index with the risk of
type 2 diabetes: A case-control study nested in an electronic
health records system in the United States. Diabetol Metab Syndr.
6:502014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chiefari E, Tanyolac S, Paonessa F,
Pullinger CR, Capula C, Iiritano S, Mazza T, Forlin M, Fusco A,
Durlach V, et al: Functional variants of the HMGA1 gene and type 2
diabetes mellitus. JAMA. 305:903–912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chiefari E, Tanyolaç S, Iiritano S,
Sciacqua A, Capula C, Arcidiacono B, Nocera A, Possidente K, Baudi
F, Ventura V, et al: A polymorphism of HMGA1 is associated with
increased risk of metabolic syndrome and related components. Sci
Rep. 3:14912013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Melillo RM, Pierantoni GM, Scala S,
Battista S, Fedele M, Stella A, De Biasio MC, Chiappetta G, Fidanza
V, Condorelli G, et al: Critical role of the HMGI(Y) proteins in
adipocytic cell growth and differentiation. Mol Cell Biol.
21:2485–2495. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang KD, Liu J, Jovanovic L, An J, Hill
MM, Vela I, Lee TK, Ma S, Nelson C, Russell PJ, et al: Adipocytes
promote prostate cancer stem cell self-renewal through
amplification of the cholecystokinin autocrine loop. Oncotarget.
7:4939–4948. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Uddin S, Bu R, Ahmed M, Abubaker J,
Al-Dayel F, Bavi P and Al-Kuraya KS: Overexpression of leptin
receptor predicts an unfavorable outcome in Middle Eastern ovarian
cancer. Mol Cancer. 8:742009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Saxena NK, Sharma D, Ding X, Lin S, Marra
F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT,
PI3K/AKT and ERK signaling is involved in leptin-mediated promotion
of invasion and migration of hepatocellular carcinoma cells. Cancer
Res. 67:2497–2507. 2007. View Article : Google Scholar : PubMed/NCBI
|
